Acadia Pharmaceuticals Inc. (ACAD) said Wednesday that its Phase 3 COMPASS PWS study of carbetocin for the treatment of patients with hyperphagia or extreme hunger associated with Prader-Willi syndrome failed to meet its primary endpoint.
COMPASS PWS was a 12-week, randomized, placebo-controlled global Phase 3 trial evaluating the efficacy and safety of intranasal carbetocin in individuals aged 5 to 30 years with Prader-Willi syndrome (PWS), a rare genetic disorder. The trial found that intranasal carbetocin did not show a statistically significant improvement over placebo on the primary endpoint—the change from baseline to Week 12 on the Hyperphagia Questionnaire for Clinical Trials (HQ-CT), a caregiver-reported measure of food-seeking behaviors in individuals with PWS.
The safety and tolerability profile of intranasal carbetocin was consistent with previous trials, with a low rate of adverse events.
For comments and feedback contact: editorial@rttnews.com
Business News
December 19, 2025 15:10 ET U.S. inflation data and interest rate decisions by major central banks were the highlights of this busy week for economics news flow. Employment data and survey results on the housing markets also gained attention in the U.S. In Europe, the European Central Bank and Bank of England announced their policy decisions and macroeconomic projections.